Frozen and cold-stored platelets: reconsidered platelet products.

Platelet transfusion, both prophylactic and therapeutic, is a key element in modern medicine. Currently, the standard platelet product for clinical use is platelet concentrates at room temperature (20-24°C) under gentle agitation. As this temperature favors bacterial growth, storage is limited to 5-7 days, which result in high wastage rate, and complicates inventory and product availability at remote areas.

Compliance with temperature and time requirements during in-hospital distribution of blood components: A national survey among transfusion services.

Introduction: Temperature and time conditions during storage and distribution of blood components (BC) and their permissible deviations are strictly regulated. The degree of compliance with these requirements in daily practice of transfusion services (TS) is not well known.

Materials And Methods: We conducted a survey among Spanish hospital TS covering different aspects of BC management in their daily activity.

Proteomic analysis of extracellular vesicles derived from platelet concentrates treated with Mirasol® identifies biomarkers of platelet storage lesion.

In blood banks, platelets are stored until 7 days after a pathogen reduction technology (PRT) treatment, Mirasol® (vitamin B plus UVB light) in the present case. The storage time under these conditions may have an impact on platelets and their releasate leading to potential adverse reactions following transfusion to patients. The aim of this study was to analyze the proteome of extracellular vesicles generated by platelets at different storage days (2 and 7) to gain deeper information on the platelet concentrates state at those moments.

Collection, storage, inspection and quality control of platelet concentrates obtained by apheresis: The situation in Spain.

Background: Diverse variables are involved in apheresis platelet collection, processing and storage. This survey shows how these are realized in Spain.

Method: An analysis of collected data was performed in a questionnaire completed by ten Transfusion Centers (TC) which perform between 50 and 520 apheresis procedures per month.

Assessment of the Clinical Performance of Platelet Concentrates Treated by Pathogen Reduction Technology in Santiago de Compostela.

Introduction: This study assessed the feasibility, performance, and safety of Mirasol®-treated platelet concentrates (M-PC) stored for up to 7 days.

Methods: This prospective observational study was approved by the ethical committee of the University Clinic of Santiago de Compostela. Informed consent was asked from patients receiving M-PC.

In vitro evaluation of platelet concentrates suspended in additive solution and treated for pathogen reduction: effects of clumping formation.

Background: Platelet concentrates may demonstrate visual, macroscopic clumps immediately after collection following aphaeresis or production from whole blood, independently of the preparation method or equipment used. The relationship between the occurrence of clumping and their effect on in vitro quality of platelets was investigated.

Material And Methods: Platelet concentrates, suspended in SSP+ additive solution (Macopharma), were obtained by automated processing and also from routine processing.

Treatment of buffy coat platelets in platelet additive solution with the mirasol(®) pathogen reduction technology system.

Background: The Mirasol pathogen reduction technology (PRT) system uses riboflavin and ultraviolet light and is currently approved and used in Europe for the treatment of platelets and plasma. Mirasol treatment is intended to reduce the infectious pathogen load and to inactivate leukocytes in blood products. Our objective was to evaluate buffy coat platelet concentrates (BCPCs) prepared with platelet additive solution (PAS) and treated with the Mirasol system and to examine the effects on platelet cell quality during storage.